18 August 2026 | 11:02PM HKT Equity Research Genscript Biotech Corp. (1548.HK): Earnings Review: 1H26 beat on strong LSG/AIDD; AI-driven demand fuels sharp guidance upgrade; TP 1H26 beat on strong AIDD demand, FY26 guidance raised led by LSG: 1H26 revenue came at US$404mn (+27% y/y ex-LaNova licensing, 5% above GSe of US$384mn), primarily attributed to strong LSG (US$319mn vs. GSe US$295mn) with quickly growing AIDD demand. With higher-than-expected GM at 51% (vs. GSe of 45%), mainly driven by the strong LS ...